Drug-induced nail disorders. Incidence, management and prognosis

Drug Safety

Volumn 21, Issue 3, 1999, Pages 187-201

  Piraccini, Bianca Maria ^a   Tosti, Antonella ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETANILIDE; ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANDROGEN; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ARSENIC; BIOTIN; CARBAMAZEPINE; CAROTENOID; CEFALORIDINE; CHROMIUM DERIVATIVE; CORTICOTROPIN; CORTISONE; CYCLOSPORIN; FLUORINE; INTERMEDIN; ORAL CONTRACEPTIVE AGENT; PARATHYROID EXTRACT; PSORALEN; PSORALEN DERIVATIVE; RETINOID; RETINOL; SALBUTAMOL; SUCCIMER; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG; ZIDOVUDINE;

BLOOD FLOW; DRUG INDUCED DISEASE; HUMAN; INCIDENCE; ISCHEMIA; MELANOSIS; NAIL; NAIL BED; NAIL DISEASE; NAIL DYSTROPHY; NAIL HYPOPLASIA; NAIL PIGMENTATION; ONYCHOLYSIS; PARONYCHIA; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

FEMALE; HUMANS; NAIL DISEASES; NAILS; PIGMENTATION DISORDERS; PREGNANCY; PROGNOSIS; REGIONAL BLOOD FLOW;

EID: 0032886641     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199921030-00004     Document Type: Review

References (51)

1. Zaias N. The nail in health and disease. 2nd rev. ed. Norwalk: Appleton & Lange, 1990
2. Tosti A, Baran R, Dawber RPR. The nail in systemic diseases and drug-induced changes. In: Baran R, Dawber RPR, editors. Diseases of the nails and their management. 2nd ed. Oxford: Blackwell Scientific Publications, 1994; 175-261
3. Daniel III CR, Scher RK. Nail changes secondary to systemic drugs or ingestants. J Am Acad Dermatol 1984; 10: 250-8
4. Baran R, Dawber R, Hancke E, et al. A text atlas of nail disorders. London: Martin Dunitz, 1996
5. Singh M, Kaur S. Chemotherapy-induced multiple Beau's lines. Int J Dermatol 1986; 25: 590-1
6. Baran R. Retinoids and the nails. J Dermatol Treat 1990; 1: 151-4
7. Eastwood JB, Curtis JR, Smith EKM, et al. Shedding of nails apparently induced by the administration of large amounts of cephaloridine and cloxacillin in two anephric patients. Br J Dermatol 1969; 81: 750-2
8. Baran R, Témìme P. Les onychodystrophics toxi-medicamenteuses et les onycholyses. Concours Med 1973; 95: 1007-23
9. Chapman S, Cohen PR. Transverse leukonychia in patients receiving cancer chemotherapy. South Med J 1997; 90: 395-8
10. Thomas HM. Transverse bands in fingernails. Bull Johns Hopkins Hosp 1964; 115: 238-44
11. Miller E. Levodopa and nail growth. N Engl J Med 1973; 208: 916
12. de Doncker P, Pierard GE. Acquired nail beading in patients receiving itraconazole - an indicator of faster nail growth?: a study using optical profilometry. Clin Exp Dermatol 1994; 19: 404-6
13. Shelley WB, Shelley ED. A dermatologic diary: portrait of a practice. Cutis 1992; 49: 385-92
14. Blumental G. Paronychia and pyogenic granuloma-like lesions with isotretinoin. J Am Acad Dermatol 1984; 4: 677-8
15. Knight JF. Side benefits of the pill [letter]. Med J Aust 1974; Nov: 680
16. Chang JC. Acute bullous dermatosis and onycholysis due to high-dose methotrexate and leucovorin calcium. Arch Dermatol 1987; 123: 990-2
17. Baran R. Action thérapeutique et complications du rétinoide aromatique sur l'appareil ungućal. Ann Dermatol Venereol 1982; 109: 367-71
18. Baran R. Les onycholyses. Ann Dermatol Venereol 1986; 113: 159-70
19. Baran R, Juhlin L. Drug induced photo-onycholysis: three subtypes identified in a study of 15 cases. J Am Acad Dermatol 1987; 17: 1012-6
20. Jeanmougin M, Morel P, Civatte J. Photoonycholyse induine par la doxycycline. Ann Dermatol Venereol 1982; 109: 165-6
21. Mackie RM. Onycholysis occurring during PUVA therapy. Clin Exp Dermatol 1979; 4: 111-3
22. Zala L, Omar A, Krebs A. Photo-onycholysis induced by 8-methoxypsoralen. Dermatologica 1977; 154: 203-15
23. Baran R, Brun P. Photo-onycholysis induced by the fluoro quinolones pefloxacine and ofloxacine. Dermatologica 1986; 176: 185-8
24. Shelley WB, Humprey GB. Transverse leukonychia (Mees lines) due to daunorubicin chemotherapy. Pediatr Dermatol 1997; 14: 144-5
25. Muchreke RC. The fingernails in chronic hypoalburninaemia [letter]. BMJ 1956; 1: 1327
26. James WD, Odom RB. Chemotherapy-induced transverse white lines in the fingernails. Arch Dermatol 1983; 119: 334-5
27. Wantzin GL, Thomsen K. Acute paronychia after high-dose methotrexate therapy. Arch Dermatol 1983; 119: 623-4
28. Baran R. Etretinate and the nails (study of 130 cases) possible mechanisms of some side-effects. Clin Exp Dermatol 1986; 11: 148-52
29. Zerboni R, Angius AG, Cusini M, et al. Lamivudine-induced paronychia [letterl. Lancet 1998; 351: 1256
30. Bouscarat F, Bouchard C, Bouhour D. Paronychia and pyogenic granuloma of the great toes in patients treated with indinavir. N Engl J Med 1998; 338: 1776-7
31. Tosti A, Piraccini BM, D'Antuono A, et al. Paronychia associated with antiretroviral therapy. Br J Dermatol 1999; 140: 1165-8
32. Baran R, Perrin C. Fixed drug eruption presenting as an acute paronychia. Br J Dermatol 1991; 125: 592-5
33. Huinink WWB, Prove AM, Piccart M, et al. A phase II trial with docetaxel (taxotere) in second line treatment with chemotherapy for advanced breast cancer. Ann Oncol 1994; 5: 527-32
34. Positano RG, De Lauro TM, Berkowitz BJ. Nail changes secondary to environmental influences. Clin Podiatr Med Surg 1989; 6: 417-29
35. Varotti C, Ghetti E, Piraccini BM, et al. Subungual hematomas in a patient treated with an oral anticoagulant (warfarin sodium). Eur J Dermatol 1997; 7: 395-6
36. Vogelzang JN, Bosl GJ, Johnson K, et al. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Int Med 1981; 95: 288-92
37. Snauwaert J, Degreef H. Bleomycin-induced Raynaud's phenomenon and acral sclerosis. Dermatologica 1984; 169: 172-4
38. Dompmartin A, Le Maitre M, Letessier D, et al. Nécroses digitales sous beta-bloquants. Ann Dermatol Venereol 1988; 115: 593-6
39. Tosti A, Piraccini BM, Baran R. The melanocyte system of the nails and its disorders. In: Nordlund JJ, Boissy RE, Hearing VJ, et al. editors. The pigmentary system. New York: Oxford University Press, 1998; 937-43
40. Nixon DW. Alterations in nail pigment with cancer chemotherapy. Arch Int Med 1976; 136: 1117-8
41. Tosti A, Gaddoni G, Fanti PA, et al. Longitudinal melanonychia induced by 3′-azidodeoxythymidine. Dermatologica 1990; 180: 217-20
42. Shelley WB, Rawnsley HM, Pillsbury DM. Postirradiation melanonychia. Arch Dermatol 1964; 90: 174-6
43. Urabe K, Nakayama J, Hori Y. Mixed epidermal and dermal hypermalanosis. In: Nordlund JJ, Boissy RE, Hearing VJ, et al, editors. The pigmentary system. New York: Oxford University Press, 1998; 909-35
44. Hendricks AA. Yellow lunulae with flourescence after tetracycline therapy. Arch Dermatol 1980; 116: 438-40
45. Tosti A, Piraccini BM, Guerra L, et al. Reversible melanonychia due to clofazimine [abstract no. 183 A]. 18th World Congress of Dermatology; 1992 Jun 12-18; New York, 183
46. Fam AG, Paton TW. Nail pigmentation after parenteral gold therapy for rheumatoid arthritis: 'gold nails'. Arthritis Rheum 1984; 27: 119-20
47. Pepine M, Flowers FP, Ramos-Caro F. Extensive cutaneous hyperpigmentation caused by minocycline. J Am Acad Dermatol 1993; 28: 292-5
48. Tuffanelli D, Abraham RK, Dubois EI. Pigmentation from antimalarial therapy. Arch Dermatol 1963; 88; 113-20
49. Jager-Roman E, Deichl A, Jakob S, et al. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. J Pediatr 1986; 108: 997-1004
50. Baran R, Kechijian P. Longitudinal melanonychia: diagnosis and management. J Am Acad Dermatol 1989; 21: 1165-75
51. Hochman LG, Scher RK, Meyerson MS. Brittle nails: response to daily biotin supplementation. Cutis 1993; 51: 303-5